查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2014475

干眼症市场：依产品类型、治疗方法、最终用户和通路划分－2026-2032年全球市场预测

Dry Eye Syndrome Market by Product Type, Treatment Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，干眼症市场价值将达到 50.2 亿美元，到 2026 年将成长至 53.7 亿美元，到 2032 年将达到 83.5 亿美元，复合年增长率为 7.52%。

主要市场统计数据
基准年 2025 50.2亿美元
预计年份：2026年 53.7亿美元
预测年份 2032 83.5亿美元
复合年增长率 (%) 7.52%

全面说明人口趋势、临床实践变化和患者行为如何改变干眼症治疗模式。

干眼症已从一种小众眼科疾病发展成为一项多学科的临床和商业性重点，其驱动因素包括人口结构变化、诊断技术进步以及患者对生活品质 (QOL) 的期望不断提高。临床医生日益认识到，干眼症是频谱疾病，需要製定个人化的治疗方案，将缓解症状与长期眼表恢復相结合。同时，医疗保健系统正努力平衡现有治疗方法的可近性与新型医疗设备和处方药的引入，后者需要新的采购和报销机制。

对推动整个干眼症治疗生态系统快速变革的潜在科学、技术和商业性因素进行了深入分析。

干眼症的治疗格局正在经历变革性变化，重新定义了竞争格局、医疗服务模式和创新重点。对泪膜生理和眼表发炎的科学认知不断加深，治疗选择也随之扩展，治疗方向从单纯的症状缓解转向针对潜在病理生理机制的介入。因此，製造商正将研发重点转向靶向发炎、恢復腺体功能或增强黏蛋白和脂质层稳定性的药物和医疗设备，而供应商则致力于改进製剂技术和给药系统，以提高疗效和耐受性。

评估到 2025 年近期关税政策变化将如何影响干眼症药物的采购、製造和供应链韧性。

2025年将实施的贸易政策和关税措施可能对从事干眼症治疗产品和医疗设备生产、分销和销售的公司产生重大的营运和策略影响。关税税率和进口限制的变化可能会增加从海外供应商采购成品医疗设备、无菌包装系统、特殊聚合物和活性药物成分的成本。由于许多眼科产品的组件和中间体在生产过程中需要跨越多个国界，即使小幅提高关税也可能导致采购成本上升，并对製造商的利润率造成压力，从而促使企业重新审视其筹资策略。

将产品形式、治疗领域、通路和最终用户环境与商业性机会和临床需求连结起来的策略性細項分析。

细分市场洞察为根据独特的临床和商业性需求调整开发平臺、商业化策略和通路投资提供了切实可行的观点。观察产品类型细分——例如医疗设备、眼药水、眼用凝胶、眼膏和泪小管栓塞——可以清楚展现配方复杂性、患者依从性和资本密集度方面的机会和限制因素。虽然医疗设备和泪小管栓塞通常需要大量的初始投资和临床检验成本，但它们能够提供持续的治疗效果并减轻用户的长期负担；而滴眼液、凝胶和眼膏的上市週期较短，并且允许进行迭代产品改进，重点关注配方稳定性和无防腐剂技术。

区域性洞察揭示了监管、支付方和临床应用趋势的多样性，从而塑造了世界各地不同的策略。

区域趋势既揭示了通用的挑战，也揭示了独特的市场驱动因素，因此需要製定能够考虑到细微区域差异的策略。在美洲，病患意识的提高、私人医疗服务模式的完善以及成熟的临床路径促进了处方药疗法和先进医疗设备的快速普及。同时，支付方结构和报销体系的细微差异会影响产品推出时间和定价策略。区域内的跨境生产为寻求供应链弹性的公司提供了优势，但监管时效和采购流程的区域差异要求制定有针对性的市场进入计画。

对干眼症治疗解决方案的竞争定位进行了简洁而全面的概述，阐述了成熟公司、专家创新者和策略伙伴关係如何推动差异化。

干眼症领域的竞争动态呈现出多元化的态势，既有成熟的製药公司，也有专业的医疗设备製造商，以及灵活敏捷的中小型创新企业。成熟的製药公司凭藉其完善的商业基础设施、丰富的监管经验和大规模的生产能力，维持着涵盖处方药和非处方药的广泛产品系列。它们的优势在于与支付方、医院系统和分销网络建立了稳固的合作关係，这为新适应症和产品线的快速拓展提供了有力支持。同时，专业的医疗设备製造商和Start-Ups正透过推出针对性的创新产品，例如新型给药平台、诊断设备和基于生物资讯的製剂，挑战成熟製药公司的地位，从而提供差异化的临床价值并提升患者的就医便利性。

为领导者提供切实可行的建议，透​​过协调证据产生、价值链韧性和多通路商业化来实现永续价值。

对于致力于将知识转化为行动的产业领导者而言，以下几项策略重点有助于维持利润率、加速患者接受度并建立可持续的竞争优势。首先，将临床证据的取得与商业规划结合至关重要。使临床实验设计和真实世界数据 (RWE) 的收集与支付方和临床医生的期望保持一致，可以缩短决策时间并提高保险覆盖率（纳入医保报销范围）。投资于差异化的给药系统和不含防腐剂的配方可以提高患者的用药依从性，为高价定位提供依据，并消除临床医生对长期眼毒性的担忧。

为了检验研究结果并确保研究的严谨性，我们将对我们的混合方法研究途径进行透明的解释，该方法结合了临床医生参与、文献整合和贸易政策审查。

本分析的调查方法结合了定性和定量方法，以确保获得全面且可重复的见解。主要调查包括对眼科医疗保健生态系统中的临床专业人员、采购经理和商业领导者进行结构化访谈，以了解从业人员对未满足的需求、推广障碍和新临床实践的观点。此外，专家圆桌会议和咨询会议也补充了这些讯息，有助于将临床终点和营运限制置于具体情境中。

结论：整合是实现永续影响的途径，强调临床创新、营运韧性和策略商业化的整合。

总而言之，干眼症的治疗正处于一个策略转折点，临床进展、患者期望和商业性现实在此交汇融合。该领域正朝着以长期眼表健康而非暂时控制症状为优先的治疗方法和医疗设备方向发展，同时，数位化诊断和远距医疗模式正在重塑患者的治疗路径。贸易政策和供应链的考量进一步增加了复杂性，迫使企业重新评估其采购、製造地和经销伙伴。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：干眼症市场：依产品类型划分

  • 医疗设备
  • 眼药水
  • 眼药凝胶
  • 眼膏
  • 泪管栓塞

第九章：干眼症市场（依治疗方法划分）

  • 人工泪液
  • 医疗设备
  • 营养保健品
  • 处方药治疗
    • 皮质类固醇
    • Cyclosporine
    • 重新定义 Grast

第十章：干眼症市场：依最终用户划分

  • 诊所
  • 居家照护
  • 医院

第十一章：干眼症市场：依分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章 干眼症市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 干眼症市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 干眼症市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国干眼症市场

第十六章：中国干眼症市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • AFT Pharmaceuticals Ltd.
  • Akorn Operating Company LLC
  • Alcon Inc.
  • Bausch+Lomb Corporation
  • Jianfeng Group Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • Kala Pharmaceuticals, Inc.
  • Mitotech SA
  • Novaliq GmbH
  • Novartis AG
  • OASIS Medical, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Rohto Pharmaceutical Co., Ltd.
  • Santen Pharmaceutical Co., Ltd.
  • Senju Pharmaceutical Co., Ltd.
  • Similasan Corporation
  • Sun Pharmaceutical Industries Ltd.
  • Thea Pharmaceuticals Ltd.
  • United Laboratories Co., Ltd.
  • Ursapharm Arzneimittel GmbH
Product Code: MRR-4348D129FA98

The Dry Eye Syndrome Market was valued at USD 5.02 billion in 2025 and is projected to grow to USD 5.37 billion in 2026, with a CAGR of 7.52%, reaching USD 8.35 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.02 billion
Estimated Year [2026] USD 5.37 billion
Forecast Year [2032] USD 8.35 billion
CAGR (%) 7.52%

Comprehensive introduction explaining how demographic trends, clinical practice changes, and patient behavior are reshaping the dry eye treatment landscape

Dry eye syndrome has evolved from a niche ophthalmic complaint into a multidisciplinary clinical and commercial priority, driven by demographic shifts, evolving diagnostic sophistication, and growing patient expectations for quality-of-life outcomes. Clinicians increasingly recognize dry eye as a spectrum disorder with variable etiology, requiring personalized care pathways that combine symptomatic relief with long-term ocular surface restoration. Concurrently, healthcare systems are grappling with balancing access to established therapies and the introduction of novel medical devices and prescription agents that demand new procurement and reimbursement approaches.

In parallel, patients' care-seeking behavior and engagement with digital tools have changed the interface between providers and manufacturers. Telehealth consultations and remote monitoring have expanded triage capabilities and accelerated diagnosis in primary care and ophthalmology practices, while direct-to-consumer communication has elevated awareness and created a more informed patient population. This shift compels industry stakeholders to integrate clinical evidence with user-centered design and to streamline patient adherence through simplified regimens and better education. As a result, cross-functional collaboration across product development, regulatory affairs, and commercial strategy is becoming essential to translate scientific advances into measurable patient benefit and sustainable business models.

Insightful analysis of the fundamental scientific, technological, and commercial forces driving rapid transformation across the dry eye treatment ecosystem

The landscape for dry eye management is undergoing transformative shifts that are redefining competition, care delivery, and innovation priorities. Scientific advances in understanding tear film physiology and ocular surface inflammation have broadened the therapeutic toolbox, encouraging transitions from purely symptomatic care to interventions that address underlying pathophysiology. Consequently, manufacturers are refocusing pipelines toward agents and devices that target inflammation, restore gland function, or enhance mucin and lipid layer stability, while suppliers are investing in improved formulation technologies and delivery systems to increase efficacy and tolerability.

At the same time, digital health integration is emerging as a powerful enabler for both diagnosis and adherence monitoring. Technologies that capture objective metrics such as tear osmolarity, meibomian gland imaging, and blink pattern analysis are moving from research into clinical practice, supporting data-driven treatment selection. On the commercial front, distribution and purchasing models are shifting; digital pharmacies and cross-channel partnerships are influencing product availability and patient access. Taken together, these factors are encouraging companies to pursue differentiated value propositions that combine clinical evidence, patient experience enhancements, and scalable commercial models to secure durable positioning in a more sophisticated care environment.

Assessment of how recent tariff policy changes through 2025 can reshape procurement, manufacturing, and supply chain resilience for dry eye therapies

Trade policies and tariff actions enacted through 2025 have the potential to create meaningful operational and strategic consequences for companies involved in the manufacture, distribution, and sale of dry eye therapeutics and devices. Changes in duty rates and import regulation can increase landed costs for finished medical devices, sterile packaging systems, specialty polymers, and active pharmaceutical ingredients sourced from international suppliers. Because many components and intermediates in ophthalmic products cross multiple borders during manufacturing, even incremental tariff increases can cascade into higher procurement expenses and compress manufacturer margins, prompting reassessment of sourcing strategies.

In response to tariff pressure, firms typically pursue a range of mitigation tactics. These include shifting supply toward nearer-shore partners, renegotiating long-term supplier contracts to lock in pricing, and redesigning product packaging or components to minimize tariff exposure. Regulatory compliance and customs clearance processes may require additional documentation and validation, extending lead times and complicating inventory planning. For distributors and pharmacies, tariff-driven cost increases can influence pricing and reimbursement negotiations, while health systems may re-evaluate preferred supplier lists to contain procurement costs. Moreover, policy uncertainty itself can accelerate investment in supply-chain resilience, including increased safety stock, multi-sourcing strategies, and localized manufacturing capacity. Ultimately, the cumulative policy environment through 2025 underscores the need for integrated trade and commercial planning to preserve access, manage cost structures, and sustain innovation.

Strategic segmentation analysis linking product formats, therapeutic categories, distribution pathways, and end-user settings to commercial opportunity and clinical demand

Segmentation insights provide a practical lens for tailoring R&D pipelines, commercialization strategies, and channel investments to distinct clinical and commercial needs. When observing the product-type segmentation that separates Devices, Eye Drops, Eye Gels, Eye Ointments, and Punctal Plugs, clear opportunities and constraints emerge across formulation complexity, patient adherence, and capital intensity. Devices and punctal plugs often require higher upfront investment and clinical validation but can deliver durable therapeutic effect and lower long-term user burden, whereas drops, gels, and ointments offer rapid time-to-market and iterative product improvements that emphasize formulation stability and preservative-free technologies.

Considering the treatment-type segmentation that encompasses Artificial Tears, Medical Devices, Nutraceuticals, and Prescription Drug Therapy-where prescription options further break down into corticosteroids, cyclosporine, and lifitegrast-strategic priorities differ sharply. Artificial tears and nutraceuticals serve well in early intervention and maintenance contexts, supporting broad access through retail channels, while prescription drug therapies necessitate deeper clinical evidence, managed care engagement, and specialty distribution pathways. Medical devices intersect both domains, requiring clinical demonstration of efficacy and the capacity to integrate with existing clinical workflows.

The distribution-channel segmentation that includes Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy highlights divergent customer journeys and margin structures. Online pharmacies enable convenience and subscription models that can enhance adherence, while hospital and retail pharmacies remain critical touchpoints for clinician-driven prescriptions and patient education. Finally, the end-user segmentation across Clinics, Home Care, and Hospitals reminds stakeholders that care settings influence product design and service expectations. Clinics prioritize rapid diagnostics and point-of-care interventions, home care demands simple-to-use regimens with robust patient instructions, and hospitals require scalable solutions that integrate into procedural and post-operative care pathways. Together, these segmentation lenses inform differentiated value propositions and prioritization of evidence generation, channel partnerships, and user-centric design.

Regional intelligence that delineates how varied regulatory, payer, and clinical adoption dynamics shape differentiated strategies across global territories

Regional dynamics demonstrate both shared challenges and distinct market drivers that call for geographically nuanced strategies. In the Americas, patient awareness, private healthcare delivery models, and established clinical pathways support rapid adoption of both prescription therapies and advanced devices, while payer structures and reimbursement nuance influence launch sequencing and pricing strategy. Cross-border manufacturing within the region also provides advantages for firms seeking supply-chain agility, yet regional differences in regulatory timing and procurement processes require targeted market entry planning.

Europe, Middle East & Africa present a complex mosaic of regulatory regimes and purchasing behaviors, where centralized reimbursement decisions in some countries contrast with decentralized procurement in others. Clinical adoption is often mediated by health-technology assessment frameworks and formulary inclusion processes, which prioritize robust comparative effectiveness and real-world evidence. Regulatory harmonization efforts can lower barriers for multi-country rollouts, yet commercial strategies must be tailored to local clinical practice patterns and distribution infrastructures.

Asia-Pacific displays marked heterogeneity driven by variations in population aging, urbanization, and healthcare investment. Several markets in this region show increasing appetite for innovative devices and prescription agents, supported by expanding specialist capacity and private sector investment. However, fragmented regulatory pathways, differences in import/export procedures, and diverse patient affordability considerations necessitate flexible pricing models and partnerships with local distributors to accelerate access. Across all regions, companies that align clinical evidence generation with local reimbursement expectations and that invest in clinician education and patient support infrastructures will be better positioned to translate scientific advances into measurable uptake.

Concise yet comprehensive view of competitive positioning showing how incumbents, specialized innovators, and strategic partnerships drive differentiation in dry eye solutions

Competitive dynamics within the dry eye domain reflect a mix of established pharmaceutical players, specialized device manufacturers, and agile smaller innovators. Established companies leverage broad commercial infrastructures, deep regulatory experience, and large-scale manufacturing to sustain portfolio breadth across prescription therapies and over-the-counter products. Their advantages include established relationships with payers, hospital systems, and distribution networks, which support rapid scaling of new indications and line extensions. At the same time, specialist device manufacturers and startups introduce targeted innovations-such as novel delivery platforms, diagnostic devices, and biologically inspired formulations-that challenge incumbents by offering differentiated clinical value or improved patient convenience.

Collaboration and consolidation are recurring themes as large organizations seek to complement internal R&D with external innovation through licensing, co-development, or M&A. Meanwhile, smaller firms often focus on niche clinical benefits or user experience advantages that can be validated in smaller, efficient trials or in real-world use cases. Distribution partnerships, cross-channel agreements with pharmacies, and value-based contracting experiments are increasingly important competitive levers. Companies that successfully integrate clinical evidence, regulatory strategy, and commercial access planning-while maintaining nimbleness to respond to emerging scientific insights-will be better equipped to convert innovation into sustainable market positions.

Action-oriented recommendations enabling leaders to align evidence generation, supply-chain resilience, and multi-channel commercialization to capture durable value

For industry leaders seeking to convert insights into action, several strategic priorities can help protect margins, accelerate patient uptake, and build durable competitive advantage. First, integrating clinical evidence generation with commercial planning is essential: aligning trial design and real-world evidence collection to payer and clinician expectations reduces time-to-decision and supports formulary inclusion. Investing in differentiated delivery systems and preservative-free formulations can enhance adherence and justify premium positioning, while simultaneously addressing clinician concerns about long-term ocular surface toxicity.

Second, companies should operationalize supply-chain resilience by diversifying supplier bases, considering near-shore manufacturing options for critical components, and embedding tariff- and regulatory-risk assessment into procurement processes. This will limit exposure to policy-driven cost shocks and improve responsiveness to demand volatility. Third, optimizing distribution requires a channel-specific approach: digital and online pharmacy strategies should be developed alongside traditional hospital and retail relationships, with tailored patient support and subscription models to sustain adherence. Lastly, fostering cross-functional partnerships-with clinical societies, payers, and technology providers-can accelerate adoption of integrated care pathways that combine diagnostics, therapeutics, and patient engagement platforms. Executed together, these measures help translate scientific promise into scalable, patient-centered care.

Transparent explanation of the mixed-methods research approach combining clinician engagement, literature synthesis, and trade policy review to validate findings and ensure rigor

The research methodology underpinning this analysis combines qualitative and quantitative approaches to ensure comprehensive, reproducible insights. Primary research consisted of structured interviews with clinical specialists, procurement directors, and commercial leaders across the ophthalmology ecosystem to capture practitioner perspectives on unmet needs, adoption barriers, and emergent clinical practice. These inputs were complemented by expert roundtables and advisory discussions that helped contextualize clinical endpoints and operational constraints.

Secondary research involved systematic review of peer-reviewed clinical literature, regulatory guidance documents, and publicly available patent and clinical-trial registries to map therapeutic mechanisms, safety profiles, and trial endpoints. Trade and policy analyses were conducted using official customs and regulatory sources to understand tariff and import-control implications. Data triangulation and cross-validation were applied to reconcile differing information streams and to highlight consensus areas versus topics requiring further evidence. Quality controls included independent review of key findings by external clinical advisors and iterative validation with industry executives to ensure that conclusions are both clinically credible and commercially relevant. Limitations include variability in public data granularity across regions and evolving policy environments, which were addressed through sensitivity analyses and explicit documentation of assumptions.

Concluding synthesis emphasizing the convergence of clinical innovation, operational resilience, and strategic commercialization as the pathway to sustained impact

In summary, the management of dry eye syndrome is at a strategic inflection point where clinical advances, patient expectations, and commercial realities intersect. The field is witnessing a transition toward therapies and devices that prioritize long-term ocular surface health rather than transient symptom control, while digital diagnostics and remote care models are reshaping patient pathways. Trade policy and supply-chain considerations add another layer of complexity, prompting firms to re-evaluate sourcing, manufacturing footprint, and distribution partnerships.

To thrive in this environment, stakeholders must adopt integrated strategies that combine rigorous evidence generation with operational resilience and targeted commercialization. This includes designing products that address specific clinical phenotypes, aligning value propositions with payer and clinician needs, and deploying multi-channel distribution approaches that meet patients where they seek care. Ultimately, success will favor organizations that balance scientific innovation with pragmatic execution and that invest in partnerships to scale patient impact efficiently.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dry Eye Syndrome Market, by Product Type

  • 8.1. Devices
  • 8.2. Eye Drops
  • 8.3. Eye Gels
  • 8.4. Eye Ointments
  • 8.5. Punctal Plugs

9. Dry Eye Syndrome Market, by Treatment Type

  • 9.1. Artificial Tears
  • 9.2. Medical Devices
  • 9.3. Nutraceuticals
  • 9.4. Prescription Drug Therapy
    • 9.4.1. Corticosteroids
    • 9.4.2. Cyclosporine
    • 9.4.3. Lifitegrast

10. Dry Eye Syndrome Market, by End User

  • 10.1. Clinics
  • 10.2. Home Care
  • 10.3. Hospitals

11. Dry Eye Syndrome Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Dry Eye Syndrome Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Dry Eye Syndrome Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Dry Eye Syndrome Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Dry Eye Syndrome Market

16. China Dry Eye Syndrome Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. AFT Pharmaceuticals Ltd.
  • 17.7. Akorn Operating Company LLC
  • 17.8. Alcon Inc.
  • 17.9. Bausch + Lomb Corporation
  • 17.10. Jianfeng Group Co., Ltd.
  • 17.11. Johnson & Johnson Services, Inc.
  • 17.12. Kala Pharmaceuticals, Inc.
  • 17.13. Mitotech S.A.
  • 17.14. Novaliq GmbH
  • 17.15. Novartis AG
  • 17.16. OASIS Medical, Inc.
  • 17.17. Otsuka Pharmaceutical Co., Ltd.
  • 17.18. Rohto Pharmaceutical Co., Ltd.
  • 17.19. Santen Pharmaceutical Co., Ltd.
  • 17.20. Senju Pharmaceutical Co., Ltd.
  • 17.21. Similasan Corporation
  • 17.22. Sun Pharmaceutical Industries Ltd.
  • 17.23. Thea Pharmaceuticals Ltd.
  • 17.24. United Laboratories Co., Ltd.
  • 17.25. Ursapharm Arzneimittel GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRY EYE SYNDROME MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DRY EYE SYNDROME MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY EYE DROPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY EYE DROPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY EYE DROPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY EYE GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY EYE GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY EYE GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY EYE OINTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY EYE OINTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY EYE OINTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY PUNCTAL PLUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY PUNCTAL PLUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY PUNCTAL PLUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY ARTIFICIAL TEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY ARTIFICIAL TEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY ARTIFICIAL TEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY MEDICAL DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY MEDICAL DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY MEDICAL DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY NUTRACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY NUTRACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY NUTRACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY CYCLOSPORINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY CYCLOSPORINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY CYCLOSPORINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY LIFITEGRAST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY LIFITEGRAST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY LIFITEGRAST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS DRY EYE SYNDROME MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA DRY EYE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA DRY EYE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA DRY EYE SYNDROME MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE DRY EYE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST DRY EYE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA DRY EYE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC DRY EYE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN DRY EYE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. GCC DRY EYE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GCC DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. GCC DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 121. GCC DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. GCC DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION DRY EYE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS DRY EYE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. G7 DRY EYE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. G7 DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. G7 DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. G7 DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. G7 DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. G7 DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. NATO DRY EYE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. NATO DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. NATO DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. NATO DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. NATO DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. NATO DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)